Allergan Aesthetics has expanded SKINVIVE by JUVÉDERM® into 35 new markets, bringing the total to 57 globally in 2025. This expansion underscores the company's commitment to enhancing global skin quality.
SKINVIVE® is an advanced skincare option for healthy-looking skin, offering long-lasting hydration as well as smoothness to the facial area with a single treatment.
According to Coherent Market Insights, the Aesthetic Medicine Market is projected to grow at a CAGR of 14.5% during 2025 to 2032. Currently, the market is at USD 222.03 Billion in 2025 and is expected to be around USD 572.86 Billion by 2032. The global aesthetic medicine market is experiencing strong growth due to the increasing demand for aesthetic treatments and increasing adoption of minimally invasive treatments around the world.
"This extensive rollout marks an exciting new era for Allergan Aesthetics, placing a greater emphasis on skin quality," said Mark Wilson, SVP, International Allergan Aesthetics. "As we observe a shift in consumer pattern towards skin health-focused solutions, we're committed to evolving our injectable portfolio. Through introducing innovative injection techniques, new treatment approaches with AA Signature™, as well as strategic product launches worldwide, our mission is to help empower practitioners deliver the best possible results for their patients."
The global skin quality market is valued at approximately USD 5.2 billion, showcasing a major shift in consumer preferences towards health, wellness, and natural aesthetics. Aesthetic patients are increasingly opting for treatments that enhance skin quality rather than pursuing overt facial changes. This trend escalates a fuelling need for subtle, natural looking enhancements that aims on better skin health along with its appearance.
Allergan Aesthetics' AA Signature™ is a holistic treatment approach that combines products like SKINVIVE® from its injectable portfolio to cater to various patient requirements.
This program focuses on improving skin quality by enhancing smoothness, hydration, and overall skin health. By adopting multiple advancements, AA Signature™ aims to deliver personalized, patient-centric aesthetic solutions.
AA Signature™, which has so far launched in 25 countries, will be showcased at the internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai, Wednesday.
Allergan Aesthetics, an AbbVie company, develops, manufactures, and markets a portfolio of leading aesthetics brands and products. Our comprehensive offerings include facial injectables, body contouring, plastics, skin care, and more. We are committed to consistently providing our customers with innovation, education, exceptional service, and a commitment to excellence—all with a personal touch.
Source:
News: Drug Manufacturer
Company: Allergan Aesthetics